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Exploring the Relationship between Medical Insurance and Vaccine Acceptance Rates
Mark C. Knouse, MD, Yennifer Lopez, Hope Kincaid, MPH and Shae Duka, BS
Lehigh Valley Health Network, Allentown, Pa.

INTRODUCTION

• Last year the National Travel and Tourism Office
estimated that 93,000,000 US travelers went
1
abroad.
• Missed opportunities for vaccination in the higher
risk group of travelers may result in increased
disease rates in this population.
2
• A previous study looking at GTEN travel clinics
noted that 28% of travelers had refused at least one
3
recommended vaccine.
• As a quality initiative to improve vaccination rates at
our travel clinic, we sought to determine if there might
be an association between the traveler’s medical
coverage and acceptance of recommended vaccines.

ABSTRACT

Background: Every year increasing numbers of US
travelers, including older/compromised individuals, are
traveling abroad. Many are at increased risk for
vaccine preventable diseases. Insurance plans typically
cover routine immunizations but do not cover many
travel vaccines. Little data has been published
regarding rates of vaccine acceptance as related to
traveler’s medical insurance, specifically the likelihood
of accepting vaccine recommendations at the time of
a pre-travel visit.
Objective: We sought to describe the relationship
between a traveler’s medical insurance and the
likelihood of accepting vaccination recommendations
at the time of pre-travel visit.
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Methods: As a QI project, we reviewed existing billing
records in comparison to vaccines ordered by the providers, between 1/4/16 – 12/29/16. Travel Medicine
notes were retrieved, all vaccine recommendations
2
were collated and matching billing information was
reviewed.
Results: A total of 696 patients were included in the
sample. Slightly more than half (58.3%) were female
and the median age was 45 years. There were 1,628
vaccines recommended with an average of 2.3 per
traveler. Of the 658 travelers with a recommended
vaccine, 31.9% declined at least one recommended
vaccine. Reasons for declining were [N (%)]: not being
concerned about the risk of illness 122(58.1), concerns
about cost 72(34.3), referral to PCP 12(5.7), and
contraindication 4(1.9). The insurance type with the
highest rate of overall vaccine acceptance was
Commercial (Non-HMO) 1,011(85.2) followed by
Medicare HMO 19(76), Medicare 130(71.4), Self-Pay
53(67.9), Medicaid HMO 12(54.5) and HMO 69(51.5).
Compared with other insurance types, Self-pay and
HMO insured travelers had lower rates of vaccine
acceptance, except for Typhoid and Yellow Fever. The
vaccine with the lowest acceptance rates was Rabies.
Conclusion: Our QI project showed that vaccine
acceptance rates varied based on the specific vaccine
recommended and insurance coverage. It is not known
whether some of these travelers ultimately received
recommended vaccines elsewhere – future studies to
explore this would be helpful to optimize the overall
health of our travelers.

RESULTS

CONCLUSIONS AND NEXT STEPS

• This review shows that 31.9% of patients declined at
least one recommended vaccine at the time of their
pre-travel visit. Many commonly recommended vaccines
were refused at the time of visit (e.g. Hepatitis A, Tdap).
• The declination of vaccines may be predicted to some
extent based on the traveler’s medical insurance and
the vaccines offered.
• The reasons given (see QRS link) for individual
vaccines seem to vary greatly, but the end
Supplementary
result is a missed opportunity for vaccination
Tables
for this at-risk population.

TABLE 1. DEMOGRAPHICS (Unit of analysis is patient)
Self-Pay
(N=29)

Commercial
(Non-HMO) (N=513)

HMO
(N=45)

Medicare
(N=86)

Medicare
HMO (N=9)

Medicaid HMO
(N=14)

29 (21-46)

41 (23-56)

29 (21-52)

69 (66-72)

71 (66.5-76)

20.5 (17.75-28.75)

Male

13 (44.8)

217 (42.3)

15 (33.3)

39 (45.3)

6 (66.7)

0 (0)

Female

16 (55.2)

296 (57.7)

30 (66.7)

47 (54.7)

3 (33.3)

14 (100)

Age (yrs.)

N= # of patients in each group Age is presented with the median and IQR

TABLE 2. OVERALL REFUSAL VS. ACCEPTANCE RATE BY
INSURANCE TYPE (Unit of analysis is vaccine)
Entire
Self-Pay
Sample
(N=78)
(N=1,628)
Vaccine Acceptance Rate 1,294 (79.5) 53 (67.9)

Commercial
HMO
(Non-HMO)
(N=134)
(N=1,187)
1,011 (85.2) 69 (51.5)

Medicare
HMO
(N=25)
130 (71.4) 19 (76)

Medicaid
HMO
(N=22)
12 (54.5)

Vaccine Decline Rate

334 (20.5)

25 (32.1)

176 (14.83)

65 (48.5)

52 (28.6)

6 (24)

10 (45.5)

Not concerned about
risk of illness

193 (57.8)

12 (48)

130 (74)

16 (24.6)

31 (59.6)

4 (66.7)

0

Concerned about cost

110 (32.9)

9 (36)

38 (21.6)

38 (58.5)

19 (36.5)

2 (33.3)

4(40)

Contraindicated

4 (1.2)

0

2 (1.1)

0

2 (3.8)

0

0

Referred to PCP

27 (8.1)

4 (16)

6 (3.4)

11 (16.9)

0

0

6 (60)

Medicare
(N=182)

41.7% Male

■Commercial
■HMO

■Medicaid HMO

658
patients had at least 1 vaccine
recommended, with a rate of 2.5
vaccine recommendations per person

ACCEPTANCE OF VACCINE BY INSURANCE TYPE

HepA

Flu

120%

120%

Meningitis

100%

100%

80%

80%

80%

80%

60%

60%

60%

60%

40%

40%

40%

40%

20%

20%

20%

20%

120%

0
*Self-Pay (n=20), Commercial (n=287), HMO (n=29),
Medicare (n=42), Medicare HMO (n=7), Medicaid HMO (n=3)

Tdap

0%

N/A
*Self-Pay (n=6), Commercial (n=107), HMO (n=9), Medicare (n=6),
Medicare HMO (n=2), Medicaid HMO (n=0)

Pneumonia

120%

0%

120%

N/A
*Self-Pay (n=2), Commercial (n=13), HMO (n=8),
Medicare (n=5), Medicare HMO (n=0), Medicaid HMO (n=1)

Typhoid

0

0%

120%

100%

100%

100%

100%

80%

80%

80%

80%

60%

60%

60%

60%

40%

40%

40%

40%

20%

20%

20%

20%

0%

0
*Self-Pay (n=10), Commercial (n=121), HMO (n=10),
Medicare (n=16), Medicare HMO (n=2), Medicaid HMO (n=1)

0%

0

N/A

N/A

*Self-Pay (n=1), Commercial (n=7), HMO (n=5),
Medicare (n=4), Medicare HMO (n=0), Medicaid HMO (n=0)

0%

Japanese Encephalitis

120%

100%

0%

68.1%
31.9%
58.1%
34.3%
1.9%
5.7%

NOTE: Unit of analysis is patient, those who declined one or more recommended vaccines included.

100%

■Medicare
■Medicare HMO

vaccine recommendations
per person

8 ded
2
6
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58.3% Female

■Self-Pay

■Accepted
■Declined
■Not concerned about risk of illness
■Concerns about cost
■Contraindication
■Referral to PCP

2.3

n=696
45 years
(24–59)

120%

REASONS FOR DECLINING RECOMMENDED VACCINES (N=210)*

*Self-Pay (n=25), Commercial (n=447), HMO (n=41),
Medicare (n=69), Medicare HMO (n=8), Medicaid HMO (n=9)

0%

N/A

• Typhoid fever vaccine and yellow fever vaccine are
more often accepted regardless of the insurance.
• Rabies vaccine was declined often and across all
insurance types.
• We will plan to use this information in our pre-visit
planning to find better ways of increasing vaccine
acceptance based on the type of insurance.
• Ultimately payers might use such data to create better
systems for preventative health care in vulnerable travelers.

LIMITATIONS

• Limitations of this review were that it was performed in
2
a single center enrolled in the Global TravEpiNet –
results may not be generalizable to other centers.
• We did not collect any follow-up data and were unable
to assess whether the travelers who declined ultimately
got their vaccines elsewhere. This is worthy of future
investigation.
• There are likely other reasons besides insurance
coverage that impact a patients decision to decline
a recommended vaccine but that data was not
assessed as part of this initiative.

Poster copy

N/A

*Self-Pay (n=0), Commercial (n=28), HMO (n=6),
Medicare (n=10), Medicare HMO (n=2), Medicaid HMO (n=0)

Yellow Fever
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NOTE: N/A means that specific vaccine was not recommended for any patient with that insurance type.
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